These analyses provide evidence that serum Ang-2 and MMP-2, and tumor HIF-1α are potential baseline efficacy biomarkers for sunitinib in advanced RCC (based on unadjusted p value comparisons to α = 0.05) that warrant further analysis, including further understanding of their prognostic versus predictive value. Here, MMP2 is linked to neoplasm.